JLP-2008 Fixed-Dose Combination Tablet Demonstrates Bioequivalence and Comparable Safety to Separate Dapagliflozin + Pioglitazone in Healthy Participants
{{output}}
Background and objectives: To establish pharmacokinetic bioequivalence and assess the safety of a single-dose administration of fixed-dose combination (FDC) tablet containing dapagliflozin 10 mg + pioglitazone 15 mg (JLP-2008) co... ...
